The impact of serum testosterone level as prognosis factor for CRPC with enzalutamide or Abraterone

Trial Profile

The impact of serum testosterone level as prognosis factor for CRPC with enzalutamide or Abraterone

Recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Oct 2015

At a glance

  • Drugs Abiraterone (Primary) ; Enzalutamide (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms PC-TES
  • Most Recent Events

    • 30 Oct 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top